As more drugs go subcutaneous, Phillips Medisize's Tony Bedford believes that high-dose biologics will become a prevalent ...

Most patients receiving a GLP-1 receptor agonist (RA) and a biologic continue co-therapy for over a year with few treatment-related adverse events.

INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, ...

Patient advocate Howard Chang’s visit to Boehringer Ingelheim’s biopharmaceutical facility revealed both how biologic ...

The idea that mental disorders are caused by a biological mechanism is linked with prolonged use of antidepressants and ...

The Food and Drug Administration said it will be taking steps to speed up the approval process for developing generic biological drugs, an effort aimed at increasing cheaper competition among ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...

Hidradenitis suppurativa is managed with biologics like adalimumab and secukinumab, approved for moderate-to-severe cases. Adalimumab, a TNF-α inhibitor, was FDA-approved in 2015, while secukinumab, ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure With its high efficiency and simplified ...

Rystiggo (rozanolixizumab) is a brand-name subcutaneous infusion that’s prescribed for myasthenia gravis. Rystiggo has interactions with some other drugs. Examples include immunoglobulins and ...